Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
Ocular Therapeutix, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.02, Ocular Therapeutix, Inc. trades at 26.4x sales and 3.1x book value. Over the last twelve months it generated about $50M of revenue and a net loss of $319M. It runs a gross margin of 87.3%, an operating margin of -680.9% and a net margin of -648.6%. It shows return on equity of -59.5%, return on invested capital of -62.9% and a free cash flow yield of -20.2%. On the balance sheet: a debt-to-equity ratio of 0.18 and a current ratio of 9.12. Over the past 52 weeks the share price ranged from $5.80 to $16.44, with a beta of 0.99.
Ocular Therapeutix, Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 1 Strong Buy, 16 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Ocular Therapeutix, Inc. (OCUL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 3.83% / 30% · (Cash+Inv) / Mkt Cap (36m) 27.6% / 30% · Interest income / Revenue 38.7% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 3.83% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 27.6% / 33% · Receivables / Mkt Cap (36m) 1.63% / 49% · Interest income / Revenue 38.7% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 3.83% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 27.6% / 33.33% · Receivables / Mkt Cap (24m) 1.63% / 33.33% · Interest income / Revenue 38.7% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 10.5% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 89.9% / 33.33% · Receivables / Avg Assets (4Q) 4.14% / 33.33% · Interest income / Revenue 38.7% / 5% | Fail |
| FTSE | Debt / Total Assets 12.1% / 33.33% · (Cash+ST Inv) / Total Assets 87.6% / 33.33% · (Cash+Recv) / Total Assets 92.8% / 33.33% · Interest income / Revenue 38.7% / 5% | Fail |
No. As of September 2026, Ocular Therapeutix, Inc. (OCUL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Ocular Therapeutix, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 38.7% of each dividend: Ocular Therapeutix, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.